87 related articles for article (PubMed ID: 38448381)
21. Comparative Study of Binding Pockets in Human CYP1A2, CYP3A4, CYP3A5, and CYP3A7 with Aflatoxin B1, a Hepato-Carcinogen, by Molecular Dynamics Simulation & Principal Component Analysis.
Saba N; Seal A
Curr Drug Metab; 2022; 23(7):521-537. PubMed ID: 35850656
[TBL] [Abstract][Full Text] [Related]
22. Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q; van der Lee M; van Gelder T; Swen JJ
Front Pharmacol; 2022; 13():912618. PubMed ID: 35784699
[TBL] [Abstract][Full Text] [Related]
23. Interplay of Vitamin D and CYP3A4 Polymorphisms in Endocrine Disorders and Cancer.
Kasarla SS; Garikapati V; Kumar Y; Dodoala S
Endocrinol Metab (Seoul); 2022 Jun; 37(3):392-407. PubMed ID: 35654576
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Alterations in DNA Methylation of
Golestanian R; Barzegar A; Mianji GR; Ebrahimzadeh MA; Fatemi B
Curr Drug Metab; 2022; 23(3):242-250. PubMed ID: 35331105
[TBL] [Abstract][Full Text] [Related]
25. Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects.
Wang X; Ding H; Li Z; Peng Y; Tan H; Wang C; Huang G; Li W; Ma G; Wei W
Signal Transduct Target Ther; 2022 Mar; 7(1):74. PubMed ID: 35292619
[TBL] [Abstract][Full Text] [Related]
26. Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib.
Liu H; Yu Y; Guo N; Wang X; Han B; Xiang X
Front Pharmacol; 2021; 12():780937. PubMed ID: 34880763
[No Abstract] [Full Text] [Related]
27. Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates.
Fujino C; Sanoh S; Katsura T
Biol Pharm Bull; 2021; 44(11):1617-1634. PubMed ID: 34719640
[TBL] [Abstract][Full Text] [Related]
28. A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs.
Molenaar-Kuijsten L; Van Balen DEM; Beijnen JH; Steeghs N; Huitema ADR
Front Pharmacol; 2021; 12():670862. PubMed ID: 34526892
[TBL] [Abstract][Full Text] [Related]
29. Taxifolin suppresses the malignant progression of gastric cancer by regulating the AhR/CYP1A1 signaling pathway.
Xie J; Pang Y; Wu X
Int J Mol Med; 2021 Nov; 48(5):. PubMed ID: 34490474
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine.
Zhang RX; Dong K; Wang Z; Miao R; Lu W; Wu XY
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452222
[TBL] [Abstract][Full Text] [Related]
31. CYP3A gene variability and cancer cells response to the treatment.
Šemeláková M; Maliničová L; Macejová M; Pristaš P
Gen Physiol Biophys; 2021 Jan; 40(1):49-59. PubMed ID: 33655890
[TBL] [Abstract][Full Text] [Related]
32. Inhibition and induction of CYP enzymes in humans: an update.
Hakkola J; Hukkanen J; Turpeinen M; Pelkonen O
Arch Toxicol; 2020 Nov; 94(11):3671-3722. PubMed ID: 33111191
[TBL] [Abstract][Full Text] [Related]
33. Recent progress of hypoxia-modulated multifunctional nanomedicines to enhance photodynamic therapy: opportunities, challenges, and future development.
Sun Y; Zhao D; Wang G; Wang Y; Cao L; Sun J; Jiang Q; He Z
Acta Pharm Sin B; 2020 Aug; 10(8):1382-1396. PubMed ID: 32963938
[TBL] [Abstract][Full Text] [Related]
34. Can CYP Inhibition Overcome Chemotherapy Resistance?
Ingelman-Sundberg M; Lauschke VM
Trends Pharmacol Sci; 2020 Aug; 41(8):503-506. PubMed ID: 32571525
[TBL] [Abstract][Full Text] [Related]
35. PXR: a center of transcriptional regulation in cancer.
Xing Y; Yan J; Niu Y
Acta Pharm Sin B; 2020 Feb; 10(2):197-206. PubMed ID: 32082968
[TBL] [Abstract][Full Text] [Related]
36. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia.
Sasako M
Expert Rev Anticancer Ther; 2019 Nov; 19(11):939-945. PubMed ID: 31661989
[No Abstract] [Full Text] [Related]
37. CYP3A4 Induction in the Liver and Intestine of Pregnane X Receptor/CYP3A-Humanized Mice: Approaches by Mass Spectrometry Imaging and Portal Blood Analysis.
Kobayashi K; Kuze J; Abe S; Takehara S; Minegishi G; Igarashi K; Kitajima S; Kanno J; Yamamoto T; Oshimura M; Kazuki Y
Mol Pharmacol; 2019 Nov; 96(5):600-608. PubMed ID: 31455676
[TBL] [Abstract][Full Text] [Related]
38. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.
Li H; Lampe JN
Arch Biochem Biophys; 2019 Sep; 673():108078. PubMed ID: 31445893
[TBL] [Abstract][Full Text] [Related]
39. Prediction of progression of chronic atrophic gastritis with Helicobacter pylori and poor prognosis of gastric cancer by CYP3A4.
Zhang F; Wang F; Chen C; Wang T; Hu J; Su R; Li X; Gu B; Tang S; Chen H; Li Y
J Gastroenterol Hepatol; 2020 Mar; 35(3):425-432. PubMed ID: 31441961
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
